No price series to chart for ONCIN.OL.
| P/E (FY) | — | Sales (TTM) | NOK 848,000 |
| Earnings (TTM) | -NOK 139.3M | ROE | −111.35% |
| Net Margin | −16424.76% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 3.09% |
Oncoinvent ASA is a clinical-stage company developing radiopharmaceutical therapies against cancer. Its lead candidate, Radspherin, is an alpha-radiation therapy for cancers that have spread to body cavities, including the peritoneum, and is being studied in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.
No price history for ONCIN.OL — it is outside the redistributable backbone (BYOK data required), so price statistics are unavailable.
No return history for ONCIN.OL, so risk analytics are unavailable.
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LLY | ELI LILLY & Co | $1.15T | 53.2 |
| JNJ | JOHNSON & JOHNSON | $642.79B | 24.2 |
| ONC | BeOne Medicines Ltd. | $477.60B | 1739.3 |
| ABBV | AbbVie Inc. | $465.02B | 111.5 |
| MRK | Merck & Co., Inc. | $325.57B | 18.1 |
| AMGN | AMGEN INC | $212.16B | 27.6 |
| ABT | ABBOTT LABORATORIES | $186.84B | 28.8 |
| GILD | GILEAD SCIENCES, INC. | $166.77B | 19.8 |
| PFE | PFIZER INC | $143.91B | 18.6 |
| SYK | STRYKER CORP | $132.87B | 41.3 |
| BMY | BRISTOL MYERS SQUIBB CO | $129.88B | 18.4 |
| ISRG | INTUITIVE SURGICAL INC | $127.82B | 46.0 |
